Silo Pharma Inc Financials
This page shows Silo Pharma Inc (SILO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn funded by repeated equity raises defines this business more than its revenue base, which remains near $72K .
Cash climbed from$3.5M to$4.7M even though operating cash flow stayed negative, so liquidity was being rebuilt from financing rather than operations. That combination shows up in the capital structure:$4.9M of financing inflow came alongside 13.3M shares outstanding, letting the company show stable cash balances while each share represented a smaller slice of the enterprise.
Research and development spending of
The balance sheet is equity-funded rather than debt-funded: liabilities were only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Silo Pharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Silo Pharma Inc has an operating margin of -5936.9%, meaning the company retains $-5937 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -6526.4% the prior year.
Silo Pharma Inc's revenue grew a modest 0.0% year-over-year to $72K. This slow but positive growth earns a score of 33/100.
Silo Pharma Inc carries a low D/E ratio of 0.21, meaning only $0.21 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 11.36, Silo Pharma Inc holds $11.36 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Silo Pharma Inc generates a -67.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -87.3% the prior year.
Silo Pharma Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Silo Pharma Inc generates $1.10 in operating cash flow (-$4.7M OCF vs -$4.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Silo Pharma Inc earns $-114.8 in operating income for every $1 of interest expense (-$4.3M vs $37K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Silo Pharma Inc generated $72K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Silo Pharma Inc reported -$4.2M in net income in fiscal year 2025. This represents an increase of 3.8% from the prior year.
Silo Pharma Inc earned $-0.50 per diluted share (EPS) in fiscal year 2025. This represents an increase of 58.0% from the prior year.
Cash & Balance Sheet
Silo Pharma Inc held $4.7M in cash against $0 in long-term debt as of fiscal year 2025.
Silo Pharma Inc had 13M shares outstanding in fiscal year 2025. This represents an increase of 197.0% from the prior year.
Margins & Returns
Silo Pharma Inc's gross margin was 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.3 percentage points from the prior year.
Silo Pharma Inc's operating margin was -5936.9% in fiscal year 2025, reflecting core business profitability. This is up 589.5 percentage points from the prior year.
Silo Pharma Inc's net profit margin was -5863.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 229.1 percentage points from the prior year.
Silo Pharma Inc's ROE was -67.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.2 percentage points from the prior year.
Capital Allocation
Silo Pharma Inc invested $2.2M in research and development in fiscal year 2025. This represents a decrease of 8.8% from the prior year.
SILO Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18K0.0% | $18K0.0% | $18K0.0% | $18K0.0% | $18K0.0% | $18K0.0% | $18K0.0% | $18K |
| Cost of Revenue | $21K0.0% | $21K0.0% | $21K+1317.9% | $1K-0.1% | $1K0.0% | $1K+0.1% | $1K0.0% | $1K |
| Gross Profit | -$3K0.0% | -$3K0.0% | -$3K-116.1% | $17K0.0% | $17K0.0% | $17K0.0% | $17K0.0% | $17K |
| R&D Expenses | $1.0M+231.1% | $306K-43.7% | $544K-24.2% | $717K+20.8% | $594K-47.9% | $1.1M+120.2% | $518K+31.8% | $393K |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $51K |
| Operating Income | -$1.6M-102.7% | -$787K+31.7% | -$1.2M+7.8% | -$1.2M-14.1% | -$1.1M+39.7% | -$1.8M-79.5% | -$1.0M-0.7% | -$1.0M |
| Interest Expense | $3K-89.7% | $33K+3591.0% | $886-46.2% | $2K-20.2% | $2K+654.0% | $274-74.7% | $1K-41.9% | $2K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.6M-86.8% | -$882K+20.6% | -$1.1M+7.8% | -$1.2M-16.8% | -$1.0M+40.4% | -$1.7M-86.3% | -$929K+0.3% | -$932K |
| EPS (Diluted) | $-0.12 | N/A | $-0.12+36.8% | $-0.19+17.4% | $-0.23 | N/A | $-0.22+29.0% | $-0.31 |
SILO Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0M-7.7% | $7.6M+19.1% | $6.4M-4.0% | $6.7M+12.8% | $5.9M-20.4% | $7.4M-13.5% | $8.6M+6.6% | $8.0M |
| Current Assets | $6.8M-7.9% | $7.4M+19.8% | $6.2M-3.3% | $6.4M+13.7% | $5.6M-21.2% | $7.1M-13.9% | $8.3M+6.9% | $7.7M |
| Cash & Equivalents | $3.9M-17.8% | $4.7M+21.2% | $3.9M-9.6% | $4.3M+38.2% | $3.1M-19.7% | $3.9M-19.6% | $4.9M+7.9% | $4.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M+2.8% | $1.3M-5.5% | $1.4M-20.7% | $1.7M-8.1% | $1.9M-20.6% | $2.4M+33.2% | $1.8M-14.2% | $2.1M |
| Current Liabilities | $705K+8.4% | $650K-8.2% | $708K-32.5% | $1.0M-11.4% | $1.2M-28.4% | $1.7M+58.5% | $1.0M-21.0% | $1.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.7M-9.9% | $6.3M+25.9% | $5.0M+1.9% | $4.9M+22.6% | $4.0M-20.3% | $5.0M-25.8% | $6.8M+13.8% | $6.0M |
| Retained Earnings | -$21.1M-8.5% | -$19.5M-4.7% | -$18.6M-6.3% | -$17.5M-7.4% | -$16.3M-6.8% | -$15.3M-12.8% | -$13.5M-7.4% | -$12.6M |
SILO Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$823K-5.4% | -$780K+18.3% | -$955K+25.7% | -$1.3M+21.6% | -$1.6M-78.8% | -$917K+31.9% | -$1.3M-84.0% | -$732K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$24K+95.5% | -$520K-444.6% | -$95K-124.6% | $388K-55.5% | $871K+2413.9% | -$38K+6.9% | -$40K-104.2% | $954K |
| Financing Cash Flow | N/A | $2.1M+235.7% | $635K | N/A | N/A | $0-100.0% | $1.7M+7.8% | $1.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SILO Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -14.8%0.0pp | -14.8%0.0pp | -14.8%-106.7pp | 91.9%0.0pp | 91.9%0.0pp | 91.9%0.0pp | 91.9%0.0pp | 91.9% |
| Operating Margin | -8846.4%-4483.2pp | -4363.3%+2024.9pp | -6388.2%+538.6pp | -6926.8%-857.1pp | -6069.7%+3990.0pp | -10059.7%-4456.0pp | -5603.6%-40.4pp | -5563.2% |
| Net Margin | -9137.4%-4247.1pp | -4890.3%+1270.2pp | -6160.5%+520.7pp | -6681.2%-959.3pp | -5721.9%+3878.8pp | -9600.7%-4447.8pp | -5152.9%+16.4pp | -5169.4% |
| Return on Equity | -29.0%-15.0pp | -14.0%+8.2pp | -22.2%+2.3pp | -24.5%+1.2pp | -25.7%+8.7pp | -34.4%-20.7pp | -13.7%+2.0pp | -15.6% |
| Return on Assets | -23.5%-11.9pp | -11.6%+5.8pp | -17.4%+0.7pp | -18.1%-0.6pp | -17.5%+5.9pp | -23.4%-12.5pp | -10.8%+0.8pp | -11.6% |
| Current Ratio | 9.65-1.7 | 11.36+2.7 | 8.70+2.6 | 6.07+1.3 | 4.73+0.4 | 4.29-3.6 | 7.91+2.1 | 5.84 |
| Debt-to-Equity | 0.24+0.0 | 0.21-0.1 | 0.27-0.1 | 0.35-0.1 | 0.470.0 | 0.47+0.2 | 0.26-0.1 | 0.35 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Silo Pharma Inc's annual revenue?
Silo Pharma Inc (SILO) reported $72K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silo Pharma Inc's revenue growing?
Silo Pharma Inc (SILO) revenue grew by 0% year-over-year, from $72K to $72K in fiscal year 2025.
Is Silo Pharma Inc profitable?
No, Silo Pharma Inc (SILO) reported a net income of -$4.2M in fiscal year 2025, with a net profit margin of -5863.5%.
What is Silo Pharma Inc's gross margin?
Silo Pharma Inc (SILO) had a gross margin of 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Silo Pharma Inc's operating margin?
Silo Pharma Inc (SILO) had an operating margin of -5936.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Silo Pharma Inc's net profit margin?
Silo Pharma Inc (SILO) had a net profit margin of -5863.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Silo Pharma Inc's return on equity (ROE)?
Silo Pharma Inc (SILO) has a return on equity of -67.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silo Pharma Inc's operating cash flow?
Silo Pharma Inc (SILO) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Silo Pharma Inc's total assets?
Silo Pharma Inc (SILO) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Silo Pharma Inc spend on research and development?
Silo Pharma Inc (SILO) invested $2.2M in research and development during fiscal year 2025.
What is Silo Pharma Inc's current ratio?
Silo Pharma Inc (SILO) had a current ratio of 11.36 as of fiscal year 2025, which is generally considered healthy.
What is Silo Pharma Inc's debt-to-equity ratio?
Silo Pharma Inc (SILO) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silo Pharma Inc's return on assets (ROA)?
Silo Pharma Inc (SILO) had a return on assets of -55.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silo Pharma Inc's cash runway?
Based on fiscal year 2025 data, Silo Pharma Inc (SILO) had $4.7M in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Silo Pharma Inc's Piotroski F-Score?
Silo Pharma Inc (SILO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silo Pharma Inc's earnings high quality?
Silo Pharma Inc (SILO) has an earnings quality ratio of 1.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Silo Pharma Inc cover its interest payments?
Silo Pharma Inc (SILO) has an interest coverage ratio of -114.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Silo Pharma Inc?
Silo Pharma Inc (SILO) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.